CClinicalTrials.gg
Status unknownNCT05378061Updated Jun 22, 2022

Hypersensitivity to PACAP-38 in Post-Traumatic Headache

An interventional study of Pituitary adenylate cyclase activating polypeptide-38 and Placebo in Post-Traumatic Headache, sponsored by Danish Headache Center. Status unknown at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-06-22.

Sponsored by Danish Headache Center · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim is to investigate whether signaling molecule PACAP-38 induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

02

Conditions studied

  • Post-Traumatic Headache

Keywords

  • Headache
  • Pain
03

In context

Post-Traumatic Headache

188 studies on the registry are indexed under Post-Traumatic Headache; 50 are open to participants now.

This study's planned enrollment of 21 is below the median of 44 across 166 interventional studies indexed under Post-Traumatic Headache.

Browse Post-Traumatic Headache studies →

Lead sponsor

Danish Headache Center is the lead sponsor of 125 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18 to 65 years of age upon entry into screening
  • History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)
  • ≥ 4 monthly headache days on average across the 3 months prior to screening
  • Provision of informed consent prior to initiation of any study-specific activities/procedures.

Exclusion criteria

Exclusion Criteria:

  • > 1 mild traumatic injury to the head
  • History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)
  • History of moderate or severe injury to the head
  • History of whiplash injury
  • History of craniotomy
  • History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion
  • The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior
  • Female subjects of childbearing potential with a positive pregnancy test during any study visit
  • Cardiovascular disease of any kind, including cerebrovascular diseases
  • Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day
  • Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)
  • Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion
  • Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start
  • Baseline headache intensity of >3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)
  • Baseline headache with migraine-like features or self-reported baseline headache that mimics the subjects' usual headache with migraine-like features
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    PACAP-38

    A time- and volume-controlled infusion pump is used to administer PACAP-38 by intravenous infusion over 20 minutes.

    Drug: Pituitary adenylate cyclase activating polypeptide-38

  • Placebo comparator
    Placebo (isotonic saline)

    A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.

    Drug: Placebo

Interventions

  • DrugPituitary adenylate cyclase activating polypeptide-38

    Study participants will be allocated to receive continuous intravenous infusion of 10 pmol/kg/min PACAP-38.

    Also known as: PACAP-38

  • DrugPlacebo

    Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).

    Also known as: Isotonic Saline

06

What researchers measure

Primary outcomes

  1. Incidence of Migraine-Like Headache

    Difference in incidence of headache with migraine-like features (0 to 12 hours) between PACAP-38 and placebo.

    Time frame: 12 Hours

Secondary outcomes

  1. Headache Intensity Scores

    Difference in area under the curve (AUC) for headache intensity scores (0 to 12 hours) between PACAP-38 and placebo.

    Time frame: 12 Hours

07

Study locations

1 of 1 sites recruiting
  • Danish Headache Center
    Copenhagen, 2600, Denmark
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05378061
Lead sponsor
Danish Headache Center
Responsible party
Håkan Ashina (MD, Danish Headache Center) — Principal investigator
First posted
May 17, 2022
Start date
Jun 16, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Jun 22, 2022

Study contacts

Hakan Ashina, MD
Contact
haakan.ashina@regionh.dk
00 45 28 10 24 95
Hakan Ashina, MD
principal investigator · Danish Headache Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion